| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d1ad1f8d1af62ef8b12b2c47770c2e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21c08c0f5b7157094b9165e9c2ec46f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ddc66d263571e17b351f6bc7fde62ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30f56865777333f9ebb969b2c9c49851 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56 |
| filingDate |
2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baf4dc996b8bee08c8c49546680eb61c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e285fa9fe6c8d18a965fb9603fc2a64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49c407062c62ba170be7e2e430b4a2a3 |
| publicationDate |
2011-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1842857-B1 |
| titleOfInvention |
Mutant interferon proteins and use thereof |
| abstract |
It is intended to provide a mutant interferon α protein having elevated antiviral and antitumor effects and a drug for sensitive diseases containing the same as the active ingredient. This problem is solved by providing a mutant protein having an amino acid sequence derived from an amino acid sequence of human interferon α subtype α8 represented by any one of SEQ ID NOS:1 to 3 by the substitution of the arginine residue at the 145-position by a leucine residue, an isoleucine residue or a valine residue, the substitution of the alanine residue at the 146-position by an asparagine residue or a serine residue and the substitution of the methionine residue at the 149-position by a tyrosine residue and a drug for sensitive diseases containing the same as the active ingredient. |
| priorityDate |
2004-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |